Business Wire

TX-MAVENIR

Share
Mavenir’s SpamShield Messaging Technology Drives Steep Decline in Spam and Scam SMS for Globe Telecom

Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that its world-leading SpamShield messaging fraud prevention technology is driving a steep decline in the volume of spam and scam messages for Globe Telecom, Inc. in the Philippines – demonstrating its ability to disincentivize scammers and successfully boost customer protection against fraudulent, malicious and nuisance messaging. The Philippines is one of the large SMS markets in the world, and addressing the aggressive growth in the volume of spam and scam messaging is a key priority for the government’s National Telecommunications Commission (NTC).

In an impressive year-on-year improvement, Mavenir’s SpamShield has enabled the Philippines’ largest mobile operator to achieve a record 67% drop in blocked spam and scam SMS, plus a 74% decline in bank-related spam and scam messages during the first quarter of 2024, compared with the same period in 2023. The total number of blocked spam and scam SMS messages fell substantially from 1.1 billion in Q1 2023 to 362.8 million in Q1 2024. Over the same time span, the number of scam SMS messages directly reported by customers declined 44% year-on-year – from 610 in Q1 2023 to 342 in Q1 2024. Mavenir’s SpamShield technology has delivered an immediate and measurable impact for Globe – which reported blocking over 5 billion spam and scam messages in 2023 – by significantly raising the technical barriers to send fraudulent campaigns, increasing the cost of fraud, and removing profit incentives for scammers.

Mavenir’s SpamShield operates as a powerful SMS firewall – incorporating advanced monitoring, adaptive analytics, and real-time machine learning (ML) capabilities – that empowers Communication Service Providers (CSPs) to automatically block millions of fraudulent messages before they ever reach subscribers. SpamShield’s AI/ML detection algorithms adapt to current network conditions and subscriber behavior to continually detect spammer and fraudster attempts – enabling CSPs to quickly identify and act on potential threats and harmful events. This unique and innovative solution delivers an improved experience and greater security for customers, while protecting CSPs’ revenues from the negative costs of malicious activity.

Commenting on its successful spam reduction initiative, Anton Bonifacio, Chief Information Security Officer for Globe said: “Mavenir’s SpamShield technology has proven its ability to offer timely, precise, and effective threat detection and response, playing a central role in this dramatic reduction of spam and scam SMS traffic across our network to the immense benefit of all our customers. We now consider SpamShield an essential component of Globe’s anti-spam strategy moving forward, as we increase our innovation investment and strengthen our defenses against the tide of increasingly sophisticated fraudulent activity.”

Ilia Abramov, VP & GM of the Security Business Unit at Mavenir added: “Globe’s implementation of our SpamShield technology underlines its stringent and highly proactive approach to safeguarding customers, protecting users through the most robust and intelligent anti-spam messaging solution available today. The massive drop in blocked messages evidenced by these remarkable numbers shows how SpamShield achieves its transformative results in operation – making fraudulent activity prohibitively difficult and unprofitable for scammers, who then move on to easier and less protected targets including other operators and OTT channels such as WhatsApp. Globe is at the forefront of industry efforts to protect subscribers from this growing and ever-evolving array of threats, and we will continue to vigorously support its efforts to optimize communication safety and messaging authenticity in the Philippines.”

Notes to editors:

- Combating Messaging Scam and Fraud: A Telecom TV panel session with Globe recorded at MWC24: https://www.mavenir.com/resources/combating-messaging-scam-and-fraud/

About Globe:

Globe Telecom, Inc. is a leading full-service telecommunications company in the Philippines and publicly listed in the PSE with the stock symbol GLO. The company serves the telecommunications and technology needs of consumers and businesses across an entire suite of products and services including mobile, fixed, broadband, data connectivity, internet and managed services. It offers innovative digital solutions in the areas of fintech, healthtech, adtech, climatetech, shared services and venture capital. In 2019, Globe became a signatory to the United Nations Global Compact, committing to implement universal sustainability principles. Its principals are Ayala Corporation and Singtel, acknowledged industry leaders in the country and in the region.

About Mavenir:

Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529690737/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye